Streetbeat News

Earnings

MNDY

Monday.Com's stock is trading higher following the release of their Q3 results, which surpassed expectations. The company also provided a positive outlook with strong guidance for future performance.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:50 pm

CURLF

GTBIF

MRMD

PLNH

TCNNF

TRSSF

VRNOF

The recent earnings reports from eight major Multi-State Operators (MSOs) in the cannabis industry show mixed results on revenue and EBITDA, but the standout detail is the positive Cash Flow from Operations (CFFO) in Q3. Most companies beat consensus projections for CFFO, with tax deferrals being a significant driver. Investors are advised to focus on CFFO rather than revenue or EBITDA, and to distinguish between repeatable cash flows and future cash outflows due to deferred payments. The Viridian Cannabis Deal Tracker provides insights into capital raise and M&A activity in the cannabis sector.

Portfolio Pulse from Viridian Capital Advisors

November 13, 2023 | 4:47 pm

RLX

RLX Technology's stock price has increased following the announcement of their Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:46 pm

ABT

DXCM

MDT

PEN

PODD

TNDM

Medical device and diabetes care stocks are trading higher following the presentation of SELECT data by Novo Nordisk. Raymond James commented that the data presented did not contain major surprises and could be considered as 'modestly de-risking' for the sector.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:38 pm

STNE

StoneCo Ltd (NASDAQ:STNE) stock is trading higher after reporting Q3 earnings of 27 cents per share, surpassing the consensus estimate of 22 cents. Sales reached $643.35 million, also beating the estimate of $610.17 million. The stock saw heavy trading volume with over 7.9 million shares traded, compared to the 100-day average of 4.574 million shares. The positive earnings report has led to a 10% increase in STNE's stock price to $11.83.

Portfolio Pulse from Erica Kollmann

November 13, 2023 | 4:37 pm

STNE

StoneCo's stock price is on the rise following the release of their third-quarter financial results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:37 pm

HSIC

MNDY

MNTK

TTI

Monday.com Ltd. (MNDY) reported Q3 earnings that surpassed expectations, with adjusted EPS of $0.64 compared to the estimated $0.20, and sales of $189.19 million against the forecasted $182.36 million. The company expects Q4 revenue between $196 million and $198 million, and FY23 revenue between $723 million and $725 million. MNDY shares rose 9.9% to $154.03. Other stocks also moved higher, including Montauk Renewables (MNTK), TETRA Technologies (TTI), and Henry Schein (HSIC), following upgrades, partnerships, and positive earnings reports.

Portfolio Pulse from Lisa Levin

November 13, 2023 | 4:30 pm

KYMR

Kymera Therapeutics announced positive Phase 1 trial results for KT-474, published in Nature Medicine. KT-474, an IRAK4 degrader, showed robust degradation and pathway inhibition with a favorable safety profile in HS and AD patients. The trial indicated a reduction in inflammatory biomarkers and improvement in symptoms. Sanofi is conducting Phase 2 trials of KT-474 for HS and AD. Kymera's stock symbol is KYMR.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 4:04 pm

IMMR

Immersion Corporation (NASDAQ:IMMR) reported a decline in Q3 FY23 revenue by 32.3% year-over-year to $9.48 million, surpassing consensus estimates of $7.35 million. Royalty and license revenues decreased compared to the previous year, and adjusted EPS fell from $0.25 to $0.12. Operating income also declined by 40.4% Y/Y, with a reduced margin. IMMR repurchased shares and reduced operating expenses. The company announced a 50% increase in its quarterly dividend to $0.045 per share. Immersion is pursuing legal action against Meta Platforms, Inc. for alleged patent infringement. IMMR shares dropped by 7.23% to $6.22.

Portfolio Pulse from Akanksha Bakshi

November 13, 2023 | 4:02 pm

NRXP

NRX Pharmaceuticals (NASDAQ:NRXP) is scheduled to release its quarterly earnings report on November 14, 2023. Analysts predict an EPS of $-0.12. Investors will be looking for an earnings beat and positive guidance for future growth. Historically, NRXP's stock price has reacted to past earnings performances, with a mix of positive and negative changes post-announcement. The stock is currently trading at $0.3299, down 64.57% over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 4:02 pm